Latest News
& Press Releases

A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.

Alcon announced it is buying out Aerie Pharmaceuticals for about $770 million to gain access to the ophthalmic pharma firm’s open-angle glaucoma and ocular hypertension treatments.

Shares of Foghorn are tumbling after the FDA placed a full clinical hold on a Phase I dose escalation study that had already been subject to a partial hold following a patient death.

A combination of Novo Nordisk’s CagriSema injection for overweight people with type II diabetes resulted in a 15.6% body weight reduction compared to taking the drugs individually.

Elon Musk has reportedly gotten in touch with Synchron, a company developing a brain-computer interface (BCI) device, to explore potential investment opportunities, according to a report by Reuters.

Across the United States, Clusters of innovation have created self-sustaining ecosystems that are shaping the future of the life sciences industry - and driving economic growth.

Tessa Therapeutics has tapped former Takeda executive Thomas Willemsen as the man to take its CAR-T portfolio forward.

Monkeypox is a viral zoonotic disease caused by the monkeypox virus, a member of the orthropox genus in the family poxviridae.

In a letter to shareholders, RegeneRx provided a pipeline update for investors Monday, outlining plans to potentially move forward with a new asset in light of development delays.

Pfizer is to report initial data from a randomized trial of the second course of therapy of paxlovid in COVID-19 rebound patients by Sept. 2023.

With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.

Gilead’s regulatory win could open the doors for patients with complicated medication histories and for whom viral suppression regimens have become difficult to create.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments